CRVS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Mkt Cap

$801.7M

Volume

749.06K

Next Earnings

November 3rd

Loading chart

CR

CRVSCorvus Pharmaceuticals, Inc.

CRVS

Pay with—

Available Balance0.00

CR

Mkt Cap

$800.8M

Volume

749.06K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.The Motley Fool · Jun 23, 2026

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsightThe peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.GlobeNewswire Inc. · Apr 27, 2026

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data center space, though it faces legal scrutiny. USA Rare Earth gained 56% YTD, supported by $1.6 billion in federal investment and strong cash position, though it remains an early-stage firm without proven profitability.Investing.com · Feb 2, 2026

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MCorvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.GlobeNewswire Inc. · Jan 23, 2026

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockCorvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is expected to close on January 23, 2026.GlobeNewswire Inc. · Jan 22, 2026

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025Corvus Pharmaceuticals presented interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, showing promising results when combined with ipilimumab and nivolumab, with a 34% deep response rate and favorable safety profile.GlobeNewswire Inc. · Oct 17, 2025

Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 20 pharmaceutical companies are actively developing Interleukin-2 (IL-2) inhibitors to address autoimmune diseases and organ transplant procedures, with promising pipeline drugs in various clinical trial stages.GlobeNewswire Inc. · Jul 10, 2025

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing StreakU.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.Benzinga · Dec 18, 2024

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic SclerosisCorvus Pharmaceuticals presented new preclinical data showing that their lead ITK inhibitor, soquelitinib, can prevent lung damage, inflammation, and pulmonary hypertension in mouse models of systemic sclerosis, an autoimmune disease. The data supports the potential of ITK inhibition as a novel therapeutic approach for immune-mediated fibrotic diseases.GlobeNewswire Inc. · Nov 14, 2024

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate CancerCorvus Pharmaceuticals presented new data at the SITC Annual Meeting showing that their drug ciforadenant has the potential to overcome resistance to immunotherapy in metastatic castration-resistant prostate cancer. The data suggests ciforadenant can reduce immunosuppression and enhance sensitivity to anti-PD1 therapy.GlobeNewswire Inc. · Nov 9, 2024

to start trading

CR

CRVSCorvus Pharmaceuticals, Inc.

CRVS

Pay with—

Available Balance0.00

Your PositionYou don't own any CRVS yet.

Related Tickers

Earnings